Kolexia
Cattan Stéphane Gastro-entérologie
Cattan Stéphane
Gastro-entérologie
Centre Hospitalier de Lille
Lille, France
114 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Carcinome hépatocellulaire Tumeurs colorectales Ecchymose Tumeurs du foie Adénocarcinome Fibrose Tumeurs gastro-intestinales Tumeurs du pancréas

Collaborateurs

Voir plus
Edeline Julien
Edeline Julien
Centre Eugène Marquis, Rennes, France
Dharancy Sébastien
Dharancy Sébastien
Hôpital Huriez, Lille, France
Merle Philippe
Merle Philippe
Hôpital La Croix-Rousse, Lyon, France
Hebbar Mohamed
Hebbar Mohamed
Hôpital Huriez, Lille, France

Industries

Voir plus
Ipsen
14 collaboration(s)
Dernière en 2023
AstraZeneca
7 collaboration(s)
Dernière en 2023
Roche
3 collaboration(s)
Dernière en 2021
BMS
2 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma
JHEP reports : innovation in hepatology   28 janvier 2024
Conventional cytotoxic chemotherapy for gastrointestinal cancer in patients with cirrhosis: A multicentre case-control study.
Liver international : official journal of the International Association for the Study of the Liver   30 novembre 2023
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224): A Phase 2 Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects With Advanced Hepatocellular Carcinoma (KEYNOTE-224)
Essai Clinique (Merck & Co.)   11 octobre 2023
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012): A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)
Essai Clinique (Merck & Co.)   11 septembre 2023
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937): A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma and Complete Radiological Response After Surgical Resection or Local Ablation (KEYNOTE-937)
Essai Clinique (Merck & Co.)   06 septembre 2023
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial.
Liver cancer   14 février 2023
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research   14 juin 2022
Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma (aHCC): 3-year follow-up of the phase 2 KEYNOTE-224 study.
2022 ASCO Annual Meeting I   02 juin 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.
Journal of experimental & clinical cancer research : CR   02 juin 2022
SO-13 Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the open-label, phase 2 KEYNOTE-224 study
Abstract Book of the ESMO 24th World Congress on Gastrointestinal Cancer 2022, Barcelona, Spain, 29 June -2 July 2022   01 juin 2022